Literature DB >> 18508873

Whole-body PET/CT-mammography for staging breast cancer: initial results.

T-A Heusner1, L S Freudenberg, H Kuehl, E A M Hauth, P Veit-Haibach, M Forsting, A Bockisch, G Antoch.   

Abstract

The purpose of this study was to evaluate the feasibility and utility of a dedicated positron emission tomography (PET)/CT protocol in breast cancer patients. 40 patients with suspected recurrent breast cancer underwent whole-body PET/CT in the supine position (SP) followed by PET/CT of the breasts and axillae in the prone position (PP) using a special positioning aid. PP and SP images were compared in terms of the tumour-to-thoracic-wall distance, tumour-to-skin distance and tumour volume, diameter, density, maximal standardized uptake value (SUV(max)) and localization. The size of axillary areas, the number of intra-axillary lymph nodes, their transverse diameters, their SUV(max) and the number of distant metastases were compared between PP and SP images. Differences were tested for significance using the Student's t-test. All patients tolerated PP imaging well. Five locally recurrent breast cancers were detected, both in the SP and in the PP. Mean tumour-to-thoracic-wall distances (PP, 19 mm; SP, 8 mm; p = 0.003) and tumour-to-skin distances (PP, 10 mm; SP, 7 mm; p = 0.013) were significantly larger in the PP than in the SP. Potential thoracic wall or skin infiltration, as well as quadrant localization, were determined more easily in PP. The axillary area was wider in the PP when compared with SP (PP, 14.4 cm(2); SP, 10.6 cm(2); p<0.001). No other parameters were significantly different. In conclusion, a dedicated whole-body PET/CT examination, including PET/CT mammography, is feasible for clinical practice and may offer important information on the possible infiltration of a breast lesion into the adjacent thoracic wall and skin. Even though the axilla may be delineated more clearly in the PP, there seems to be no benefit with regard to N-staging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508873     DOI: 10.1259/bjr/69647413

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  11 in total

Review 1.  Combined PET/MRI: a new dimension in whole-body oncology imaging?

Authors:  Gerald Antoch; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

2.  Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Authors:  C Riegger; J Herrmann; J Nagarajah; J Hecktor; S Kuemmel; F Otterbach; S Hahn; A Bockisch; T Lauenstein; G Antoch; T A Heusner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-06       Impact factor: 9.236

Review 3.  Potential Clinical Applications of 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Mammography in Breast Cancer.

Authors:  Ihn-Ho Cho; Eun-Jung Kong
Journal:  Nucl Med Mol Imaging       Date:  2016-08-30

4.  Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.

Authors:  Till-Alexander Heusner; Sherko Kuemmel; Angela Koeninger; Monia E Hamami; Steffen Hahn; Anton Quinsten; Andreas Bockisch; Michael Forsting; Thomas Lauenstein; Gerald Antoch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-04       Impact factor: 9.236

5.  Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T.

Authors:  Heinrich F Magometschnigg; Pascal A Baltzer; Barbara Fueger; Thomas H Helbich; Georgios Karanikas; Peter Dubsky; Margaretha Rudas; Michael Weber; Katja Pinker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-30       Impact factor: 9.236

Review 6.  Clinical PET-MR Imaging in Breast Cancer and Lung Cancer.

Authors:  Samuel L Rice; Kent P Friedman
Journal:  PET Clin       Date:  2016-10

7.  Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging.

Authors:  William B Eubank; Jean H Lee; David A Mankoff
Journal:  PET Clin       Date:  2009-07-01

Review 8.  PET/CT and breast cancer.

Authors:  C Hegarty; C D Collins
Journal:  Cancer Imaging       Date:  2010-10-04       Impact factor: 3.909

9.  The Effects of Preoperative (18)F-FDG PET/CT in Breast Cancer Patients in Comparison to the Conventional Imaging Study.

Authors:  Young Jin Choi; Young Duck Shin; Yoon Hee Kang; Moon Soo Lee; Min Koo Lee; Byung Sun Cho; Yoon Jung Kang; Ju Seung Park
Journal:  J Breast Cancer       Date:  2012-12-31       Impact factor: 3.588

10.  The usefulness of F-18 FDG PET/CT-mammography for preoperative staging of breast cancer: comparison with conventional PET/CT and MR-mammography.

Authors:  Eun-Ha Moon; Seok Tae Lim; Yeon-Hee Han; Young Jin Jeong; Yun-Hee Kang; Hwan-Jeong Jeong; Myung-Hee Sohn
Journal:  Radiol Oncol       Date:  2013-10-08       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.